newsfilter
← Latest News
GlobeNewswire·

Longeveron Announces 2026 Second Quarter Financial Results and Provides Business Update

LGVNLGVNR
  • Longeveron anticipates top-line results from its Phase 2b ELPIS II clinical trial for laromestrocel in hypoplastic left heart syndrome (HLHS) in September 2026.
  • The company was selected as a Finalist & Milestone 2 Awardee for the XPRIZE Healthspan competition, receiving a $1.0 million award based on published data showing laromestrocel improved 6-minute walk distances in patients with aging frailty.
  • Three new independent directors joined Longeveron's Board of Directors.
  • For the quarter ended June 30, 2026, total revenues were $0.3 million, a 10% decrease from the prior year, primarily due to the absence of contract manufacturing revenue.
  • General and administrative expenses increased to $3.2 million in Q2 2026 from $2.6 million in the prior year, driven by higher legal spend & personnel costs.
  • Research and development expenses rose to $3.2 million in Q2 2026 from $3.0 million in the prior year due to increased clinical trial expenses for the ELPIS II trial.
  • The company reported a net loss of $6.1 million for the quarter ended June 30, 2026, compared to $5.0 million in the same period last year.
  • As of June 30, 2026, Longeveron held $10.1 million in cash & cash equivalents, which is expected to fund operations into the fourth quarter of 2026.
  • Laromestrocel received a patent from the China National Intellectual Property Administration covering potency assay methods for human mesenchymal stem cells.
  • The European Medicines Agency granted Longeveron Small or Medium-sized Enterprise (SME) status to assist with regulatory strategy & scientific advice.
  • The FDA granted laromestrocel Orphan Drug, Fast Track, & Rare Pediatric Disease designations for HLHS treatment, & Regenerative Medicine Advanced Therapy (RMAT) & Fast Track designations for Alzheimer's disease treatment.
  • Data from the Phase 2b trial for aging-related frailty published in Cell Stem Cell showed laromestrocel improved physical condition after nine months.
  • Additional analysis of Phase 2a data for mild Alzheimer's disease presented at the 2026 Alzheimer's Association International Conference indicated reduced neuroinflammation.
  • The FDA held a positive Type B meeting in March 2025 regarding a potential single Phase 2/3 trial design for Alzheimer's disease that could support a Biologics License Application submission.
  • Longeveron plans to initiate a Phase 2 clinical trial for pediatric dilated cardiomyopathy in 2027, following an IND application effective in July 2025.